Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Work In Process (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Work In Process for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process fell 41.48% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 41.48% decrease, with the full-year FY2025 number at $1.4 million, down 75.88% from a year prior.
  • Work In Process was $1.8 million for Q4 2025 at Aytu Biopharma, up from $862000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $5.7 million in Q2 2024 to a low of $862000.0 in Q3 2025.
  • A 5-year average of $2.8 million and a median of $2.8 million in 2022 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: soared 93.67% in 2024, then crashed 75.88% in 2025.
  • Aytu Biopharma's Work In Process stood at $2.2 million in 2021, then rose by 28.99% to $2.8 million in 2022, then fell by 4.6% to $2.7 million in 2023, then grew by 16.04% to $3.1 million in 2024, then tumbled by 41.48% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Work In Process are $1.8 million (Q4 2025), $862000.0 (Q3 2025), and $1.4 million (Q2 2025).